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Background: HIV-1 Nef is a viral accessory protein critical for AIDS progression. Nef lacks intrinsic catalytic activity
and binds multiple host cell signaling proteins, including Hck and other Src-family tyrosine kinases. Nef binding
induces constitutive Hck activation that may contribute to HIV pathogenesis by promoting viral infectivity, replication
and downregulation of cell-surface MHC-I molecules. In this study, we developed a yeast-based phenotypic screen to
identify small molecules that inhibit the Nef-Hck complex.
Results: Nef-Hck interaction was faithfully reconstituted in yeast cells, resulting in kinase activation and growth arrest.
Yeast cells expressing the Nef-Hck complex were used to screen a library of small heterocyclic compounds for their ability
to rescue growth inhibition. The screen identified a dihydrobenzo-1,4-dioxin-substituted analog of 2-quinoxalinyl-3-
aminobenzene-sulfonamide (DQBS) as a potent inhibitor of Nef-dependent HIV-1 replication and MHC-I downregulation
in T-cells. Docking studies predicted direct binding of DQBS to Nef which was confirmed in differential scanning
fluorimetry assays with recombinant purified Nef protein. DQBS also potently inhibited the replication of HIV-1 NL4-3
chimeras expressing Nef alleles representative of all M-group HIV-1 clades.
Conclusions: Our findings demonstrate the utility of a yeast-based growth reversion assay for the identification of small
molecule Nef antagonists. Inhibitors of Nef function discovered with this assay, such as DQBS, may complement the
activity of current antiretroviral therapies by enabling immune recognition of HIV-infected cells through the rescue of
cell surface MHC-I.
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HIV-1 nef encodes a small myristoylated protein re-
quired for optimal viral replication and AIDS pathogen-
esis [1,2]. Deletion of nef from the HIV-related simian
immunodeficiency virus prevents AIDS-like disease pro-
gression in rhesus macaques [3]. In addition, expression
of the nef gene alone is sufficient to induce an AIDS-like
syndrome in transgenic mice very similar to that ob-
served upon expression of the complete HIV-1 provirus
[4,5]. In humans, nef sequence variability and function
correlate with HIV disease progression over the course* Correspondence: tsmithga@pitt.edu
1Department of Microbiology and Molecular Genetics, University of
Pittsburgh School of Medicine, Bridgeside Point II, Suite 523, 15219,
Pittsburgh, PA, USA
Full list of author information is available at the end of the article
© 2013 Trible et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the orof infection [6,7]. Indeed, long-term non-progressive
HIV infection has been associated with nef-defective
strains of HIV in some cases [8-10]. These and other
studies identify the HIV-1 Nef accessory protein as a key
molecular determinant of AIDS.
Nef lacks any known intrinsic enzymatic or biochemical
function and instead exploits multiple host cell signaling
pathways to optimize conditions for viral replication and
AIDS progression [11,12]. Growing evidence identifies the
Src family kinases (SFKs) as key molecular targets for Nef
[13]. One important example is Hck, a Src family member
expressed in macrophages that binds strongly to Nef via
an SH3-mediated interaction [14,15]. Nef binding leads to
constitutive Hck activation [16,17], which may be import-
ant for macrophage survival [18] and productive infectiontd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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or c-Src is a critical first step in the downregulation of
cell-surface MHC-I by Nef, which enables immune escape
of HIV-infected cells [20-22]. Transgenic mice expressing
a Nef mutant lacking a highly conserved PxxPxR motif
essential for activation of Hck and other SFKs showed
no evidence of AIDS-like disease [23]. When the Nef-
transgenic mice were crossed into a hck-null background,
appearance of the AIDS-like phenotype was delayed with
reduced mortality [23]. These observations support an es-
sential role for Nef interactions with Hck and other SFKs
in multiple aspects of AIDS pathogenesis.
In this report, we describe the development of a yeast-
based screen to identify inhibitors of Nef signaling
through SFKs. First, we established that co-expression
with Nef leads to constitutive activation of Hck in
yeast by the same biochemical mechanism observed in
mammalian cells. The active Nef:Hck complex induced
growth arrest in yeast that was reversed with a known
SFK inhibitor, providing a basis for a simple yet powerful
screen for novel compounds. Using this system, we
screened a small chemical library of drug-like heterocy-
cles and identified a diaminoquinoxaline benzenesulfo-
namide analog that potently blocks Nef-dependent HIV
replication and MHC-I downregulation. Docking studies
and differential scanning fluorimetry assays support direct
interaction of this compound with Nef as its mech-
anism of action. Small molecules that interfere with Nef-- Hck
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Figure 1 Hck-YEEI models Csk-downregulated Hck in yeast. A) Domain
of an N-terminal unique domain (N), SH3 and SH2 domains, a kinase domain
site. In wild-type Hck, the tail sequence is Tyr-Gln-Gln-Gln (YQQQ), and require
Tyr-Glu-Glu-Ile (YEEI), which allows for Csk-independent downregulation in ye
wild-type Hck (WT), Hck-YEEI (YEEI) or the empty expression plasmid (−Hck). C
corresponding empty vector (−) as indicated. Cells were spotted onto agar se
kinase expression and incubated for 3 days at 30°C. Cultures were spotted in
phenotype. Plates were scanned and yeast patches appear as dark circles. C) I
grown in liquid culture in the presence of galactose at 30°C for 18 h. Protein e
tyrosine-phosphorylated proteins (pTyr) as well as for Hck, Csk, and actin as amediated downregulation of MHC-I molecules may repre-
sent powerful adjuvants to existing antiretroviral drugs by
thwarting the viral strategy of immune evasion.
Results
Hck-YEEI models Csk-downregulated Hck in yeast
Previous work has shown that ectopic expression of ac-
tive c-Src induces growth arrest in yeast [24-27]. Co-
expression of C-terminal Src kinase (Csk), a negative
regulator of SFKs [28], rescues Src-mediated growth
suppression by phosphorylating the c-Src negative regu-
latory tail and repressing kinase activity [26,29-31].
Using a similar yeast-based system, we have previously
shown that other members of the Src kinase family also
induce yeast growth arrest in a Csk-reversible manner
[29]. Co-expression of HIV-1 Nef selectively overcomes
Csk-mediated negative regulation for Hck, Lyn, and c-
Src, resulting in kinase re-activation and growth arrest
[29]. These observations suggest that the yeast system
may provide the basis for an inhibitor screen, as com-
pounds which block Nef-induced SFK signaling are pre-
dicted to rescue cell growth.
To simplify the yeast assay for chemical library screen-
ing, we substituted the sequence of the Hck negative
regulatory tail with the high-affinity SH2-binding motif,
Tyr-Glu-Glu-Ile (YEEI; Figure 1A). Previous work has
shown that the YEEI modification results in autophospho-
rylation of the tail, leading to intramolecular engagementpTyr
Hck
Csk
actin
- Hck WT YEEI
- +    - +    - +
C
Csk
organization of wild-type (WT) Hck and Hck-YEEI. Both kinases consist
and a negative regulatory tail with a conserved tyrosine phosphorylation
s Csk for phosphorylation. In Hck-YEEI, this sequence was modified to
ast. B) Yeast cultures were transformed with expression plasmids for
ells were co-transformed with expression vectors for Csk (+) or the
lection plates containing galactose as the sole carbon source to induce
four-fold dilutions to enhance visualization of the growth suppressive
mmunoblots from cultures shown in part B. Transformed cells were
xtracts were separated via SDS-PAGE, and immunoblotted for
loading control.
Trible et al. Retrovirology 2013, 10:135 Page 3 of 17
http://www.retrovirology.com/content/10/1/135of the SH2 domain and downregulation of kinase activity
in the absence of Csk [32]. Importantly, the X-ray crystal
structure of this modified form of Hck (referred to here-
after as Hck-YEEI) is nearly identical to that of native Hck
that has been down-regulated by Csk [32,33]. To deter-
mine whether the YEEI substitution was sufficient to
downregulate Hck in yeast, wild-type Hck and Hck-YEEI
were expressed in the presence or absence of Csk. Hck-
YEEI failed to suppress yeast growth, and showed re-
duced kinase activity compared with wild-type Hck on
anti-phosphotyrosine immunoblots of yeast cell lysates
(Figure 1B,C). Co-expression of Csk reduced wild-type
Hck kinase activity and reversed growth suppression, but
had no effect on Hck-YEEI, as it is already auto-down-
regulated. These results show that Hck-YEEI effectively
models the behavior of Csk-downregulated wild-type Hck
in yeast, supporting the substitution of Hck-YEEI for wild-
type Hck plus Csk to model downregulated Hck in yeast.
Nef activates Hck-YEEI in yeast by the same molecular
mechanism observed in mammalian cells
HIV-1 Nef activates Csk-downregulated Hck in yeast, lead-
ing to growth suppression [29]. To determine whether Nef
activates Hck-YEEI in the same manner, yeast cultures were
transformed with plasmids encoding wild-type Hck or
Hck-YEEI in the presence or absence of Csk and Nef. Csk
and Nef expression had no effect on yeast growth in the
absence of Hck (Figure 2A, columns 1–3). Wild-type Hck
suppressed yeast growth, and this effect was reversed upon
co-expression of Csk as expected (columns 4 and 5). Nef
strongly enhanced Hck-mediated growth suppression inde-
pendently of Csk (columns 6 and 7) as observed previously
[29]. Importantly, co-expression of Nef with Hck-YEEI also
induced a strong growth suppressive effect which was un-
affected by Csk (columns 8–11). Co-expression of Nef with
wild-type Hck resulted in much stronger tyrosine phos-
phorylation of yeast proteins than observed with Hck alone
or in the presence of Csk (Figure 2B, lanes 4–7). Nef pro-
duced a similar increase in the kinase activity of Hck-YEEI
(lanes 8 and 10). The effects of Nef on yeast protein-
tyrosine phosphorylation by wild-type Hck and Hck-YEEI
were unaffected by Csk (lanes 7 and 11). In all cases, a
strong inverse correlation was observed between Hck kin-
ase activity and yeast cell growth. These data establish that
Nef strongly activates Hck-YEEI and induces a growth-
suppressive phenotype very similar to that observed with
wild-type Hck. Note that all transformed yeast cultures
grew in an identical fashion when grown on glucose me-
dium, demonstrating that the growth suppressive effects
are due to induction of the Nef and Hck proteins and not a
general cytotoxic effect.
We next investigated whether the key structural determi-
nants of Nef-induced Hck activation were functional in the
yeast system. Nef binds to the Hck SH3 domain, disruptingits negative regulatory influence on the kinase domain [34].
To determine if Nef activates Hck-YEEI via this SH3
domain displacement mechanism in yeast, we substituted
the prolines in the Nef P72xxP75xR motif essential for SH3
recognition with alanines (Figure 3A), and co-expressed
this mutant (Nef-PA) with Hck-YEEI. In contrast to wild-
type Nef, the Nef-PA mutant failed to activate Hck-YEEI
and induce growth suppression (Figure 3B).
A second structural determinant of Nef interaction with
SH3 involves a hydrophobic pocket formed by several con-
served non-polar side chains in the Nef core (Phe90,
Trp113, Tyr120; Figure 3A). These residues interact with
SH3 Ile96, a residue unique to the RT loops of the Hck
and Lyn SH3 domains [35] (Figure 3A). Substitution of
Tyr120 within this Nef hydrophobic pocket with isoleucine
(Nef-Y120I) disrupts Nef-mediated Hck activation in a
rodent fibroblast model system [36]. Similarly, Nef-Y120I
was unable to activate Hck-YEEI in yeast and failed to pro-
duce growth suppression (Figure 3B). These data show that
Nef recognizes and activates Hck-YEEI in yeast through
the same mechanism observed in mammalian cells.
Chemical inhibition of Nef:Hck-YEEI activity restores
yeast growth
Because Nef-induced activation of Hck-YEEI causes growth
arrest, we predicted that inhibitors of this complex should
restore growth, thus providing the basis for an inhibitor
screen. We tested this idea with the pyrrolopyrimidine
compound A-419259, a potent inhibitor of Hck and other
SFKs [37-39]. Liquid cultures of yeast co-expressing Hck-
YEEI and Nef were grown in the presence or absence of
A-419259, and growth was monitored as the change in op-
tical density at 600 nm. As shown in Figure 4A, A-419259
rescued growth suppression by the Nef:Hck-YEEI complex
at both 1 and 5 μM in comparison to untreated cultures.
At 5 μM, A-419259 treatment was nearly as effective as
mutation of the Nef PxxP motif essential for SH3 binding
in terms of reversing growth arrest. This effect of A-419259
correlated with a decrease in tyrosine phosphorylation of
yeast proteins to control levels in the inhibitor-treated
cultures (Figure 4B). The ability of A-419259 to reverse the
growth arrest induced by the Nef:Hck-YEEI complex sug-
gested that the yeast-based system may be useful for the
identification of selective inhibitors of Nef:SFK signaling.
Yeast cultures expressing the Nef:Hck-YEEI complex
were then used to screen a chemical library of 2496 discrete
heterocyclic compounds. In the first pass, each compound
was tested in duplicate at 10 μM for its ability to increase
the growth of Nef:Hck-YEEI cultures relative to controls
incubated with the carrier solvent alone. From this primary
screen, 170 compounds were observed to restore growth of
Nef:Hck-YEEI cultures by at least 10% over untreated con-
trols. These compounds were then re-screened at 10 μM in
comparison to 5 μM A-419259, the control SFK inhibitor
A+      - +     - +       - +      - +      - +Csk:
Nef: - +      +     - - +      +      - - +      +
WT YEEI- Hck
1        2         3         4         5         6         7         8         9        10       11
+ Hck
pTyr
Hck
+   - + - +   - +   - +    - +
WT YEEI
Nef
Csk
1    2    3    4     5    6     7    8     9    10   11
+ Hck
- Hck
- +  +   - - +   +   - - +   +
Csk:
Nef:
1
4
16
D
ilu
tio
n
B
Figure 2 Nef activates Hck-YEEI in the same manner as Csk-downregulated wild-type Hck in yeast. Yeast cultures were co-transformed
with expression plasmids for wild-type Hck, Hck-YEEI, Csk, and Nef in the combinations shown. A) Cultures were grown on galactose-agar plates
and scanned as described in the legend to Figure 1. B) Immunoblots from cultures shown in panel A. Transformed cells were grown in liquid
culture in the presence of galactose at 30°C for 18 h. Protein extracts were separated via SDS-PAGE, and immunoblotted for tyrosine-phosphorylated
proteins (pTyr) and for Hck, Csk, and Nef. Note that the numbers in panel A correspond with the lanes in panel B.
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served to rescue growth to at least 25% of the values ob-
served with A-419259-treated positive controls. Each of
these compounds was then re-purchased and tested a third
time over a range of concentrations to verify growth recov-
ery of Nef:Hck-YEEI cultures compared with A-419259.
Figure 4C shows the resulting rank order of these com-
pounds relative to the A-419259 control response. Though
the activities of these compounds were lower than those
observed with the original library, the rank order of their
activities remained the same.Hit compounds from the Nef:Hck-YEEI yeast screen block
Nef-dependent HIV replication
We next evaluated hit compounds from the yeast screen
for activity in a Nef-dependent HIV replication assay.
For these experiments, we used U87MG astroglioma
cells engineered to express the HIV-1 co-receptors CD4
and CXCR4. Replication of HIV-1 NL4-3 is dependent
upon an intact viral nef gene in these cells, making them an
ideal system to evaluate leads from our Nef-directed screen
[40]. U87MG cells were infected with HIV-1 in the pres-
ence of the top five compounds identified in the yeast
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Figure 3 Activation of Hck-YEEI in yeast requires the Nef PxxPxR motif and hydrophobic pocket. A) Conserved features of the Nef:SH3
interface. The SH3 domain is shown in green, while Nef is colored blue. Side chains of conserved prolines in the Nef N-terminal region that
contact the SH3 hydrophobic surface are shown (Pro72; Pro75) along with Arg77 which forms a salt bridge with SH3 Asp100. The SH3 domain RT
loop Ile reside (Ile96; green spheres) interacts with several conserved residues that extend from the intersection of the Nef αA and αB helices to
form a hydrophobic pocket (Phe90, Trp113, Tyr120). This model was produced using the crystallographic coordinates of Lee, et al. (PDB: 1EFN)
[35]. B) Upper panel, left four lanes: growth of yeast cultures expressing wild-type Nef (WT), a Nef-PA mutant in which the PxxP motif is replaced
by AxxA (PA), the Nef hydrophobic pocket mutant Y120I (YI), or no Nef (Con). The cultures shown in the right four lanes also co-expressed
Hck-YEEI. All cultures were spotted and scanned as per the legend to Figure 1. Lower panels: Lysates from the yeast cultures shown in the top
panel were immunoblotted with anti-phosphotyrosine antibodies (pTyr) as well as Hck, and Nef antibodies.
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p24 Gag levels by ELISA. As shown in Figure 5A, com-
pounds 2 and 3 significantly suppressed HIV replication at
a concentration of 5 μM. Neither of these compounds was
cytotoxic to U87MG cells up to 50 μM, as judged by
Alamar Blue (resazurin) cell viability assay, indicating that
the inhibition of HIV replication is not due to non-specific
effects on cell growth (data not shown). Subsequent
concentration-response studies revealed that compound 2,
a dihydrobenzo-1,4-dioxin-substituted analog of N-(3-ami-
noquinoxalin-2-yl)-4-chlorobenzenesulfonamide (DQBS;
see Figure 5B for structure), potently blocked HIV repli-
cation with an IC50 value of 130 nM in this system
(Figure 5B). Because of the remarkable potency of this
compound against Nef-dependent HIV-1 replication, we
explored its mechanism of action in more detail as de-
scribed below.
We next investigated whether DQBS is active against
Nef proteins representative of the majority of HIV-1 M-
group clades. For these studies, we first resynthesized
DQBS as described under Materials and Methods, and
confirmed its structure by mass spectrometry and NMR.
We then tested the activity of newly synthesized DQBS
in replication assays with a set of HIV-1 NL4-3 chi-
meras. In these HIV-1 recombinants, the NL4-3 Nef
sequence is substituted with Nef sequences from HIV-1
subtypes A1, A2, B, C, F1, F2, G, H, J, K, as well as the
B-clade laboratory strain, SF2 [41]. This experiment wasperformed in the T-cell line CEM-T4, in which HIV-1
replication is also Nef-dependent [41]. Figure 6 shows
that DQBS inhibited the replication of wild-type HIV-1
NL4-3 as well as all eleven Nef chimeras with an IC50
value of about 300 nM. In contrast, DQBS did not affect
replication of Nef-defective HIV-1 (ΔNef), supporting a
Nef-dependent mechanism of action.
Because DQBS was identified as an inhibitor of Nef-
dependent SFK activation, we next explored whether it af-
fected Nef-dependent activation of endogenous SFK
activity in the context of HIV-1 infection. For these
experiments, CEM-T4 cells were infected with wild-type
or Nef-defective HIV-1 over a range of DQBS concentra-
tions. Endogenous SFK proteins were then immunopreci-
pitated from the infected cell lysates, and immunoblotted
with a phosphospecific antibody against the activation
loop phosphotyrosine (pY418). As shown in Figure 6B,
HIV-1 infection resulted in Nef-dependent SFK activation
loop tyrosine phosphorylation, and this effect was inhib-
ited by about 50% in the presence of DQBS. This result
shows that DQBS interferes with this Nef-dependent sig-
naling function as part of its mechanism of action.
DQBS inhibits Nef-mediated MHC-I downregulation
Nef induces downregulation of cell-surface MHC-I, allow-
ing HIV-infected cells to escape immune surveillance
by cytotoxic T-cells [20-22,42,43]. To investigate the effect
of DQBS on Nef-mediated MHC-I downregulation, the
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Figure 4 Identification of inhibitors of Nef:Hck-YEEI signaling in
yeast. A) Assay validation. Liquid cultures of yeast expressing
wild-type Hck (WT), Hck-YEEI (YEEI), and Hck-YEEI plus wild-type Nef
or the PA mutant were grown in 96-well plates for 22 h at 30°C.
Cultures expressing Hck-YEEI and Nef were also grown in the presence
of the broad-spectrum SFK inhibitor A-419259 at 1 and 5 μM under the
same conditions. Growth was recorded as change in optical density at
600 nm, and data are normalized to the percentage of growth
observed relative to cells transformed with the empty expression
plasmids. Each condition was repeated in triplicate, and the bargraph
shows the mean percentage of control growth ± S.D. The statistical
significance of the values obtained with Hck-YEEI plus Nef alone was
compared to the same cultures grown in the presence of 1 or 5 μM
A-419259 (Student’s t-test; *p = .01). B) Yeast cultures expressing Hck-
YEEI alone or Hck-YEEI plus Nef in the presence (+) or absence (−) of
5 μM A-419259 were grown in liquid medium in the presence of
galactose at 30°C for 18 h. Protein extracts were separated via SDS-
PAGE, and immunoblotted for tyrosine-phosphorylated proteins (pTyr),
Hck and Nef. C) Fifteen initial hits from the chemical library screen were
retested over a range of concentrations for rescue of growth
arrest in comparison to A-419259 (5 μM). The plot shows a ranking of
the results as a percentage of the growth reversion observed with
A-419259. Optimal concentrations varied between compounds, which
most likely reflects an effect on the Nef:Hck target vs. cytotoxicity at
higher concentrations for some compounds. Data shown were
obtained at 30 μM with the exception of compounds 3 and 10
(10 μM), 4 and 6 (3 μM), and 9 (1 μM).
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Figure 5 Hit compounds from the yeast-based Nef:Hck screen
block HIV replication. A) U87MG/CD4/CXCR4 cells were infected
with HIV strain NL4-3 in the presence of the top five compounds
selected from the Nef:Hck-YEEI yeast screen shown in Figure 4C.
Cells treated with the carrier solvent alone (DMSO) served as control.
Release of viral p24 was determined in duplicate by ELISA four days
post-infection, and the values shown reflect the mean percent of
control ± S.D. B) Dose response curve for the anti-HIV activity of
compound 2 from part A. Non-linear curve fitting was used to
estimate an IC50 value of 130 nM for this compound, which is a
dihydrobenzo-1,4-dioxin-substituted analog of N-(3-aminoquinoxalin-
2-yl)-4-chlorobenzenesulfonamide (DQBS; structure shown).
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http://www.retrovirology.com/content/10/1/135CD4+ T-cell line H9 was infected with a recombinant
vaccinia virus carrying Nef or with wild-type vaccinia virus
and then treated with increasing concentrations of DQBS.
As shown in Figure 7A, Nef expression resulted in down-
regulation of cell-surface MHC-I expression by flow cy-
tometry, consistent with previous results in this system
[20,44]. Remarkably, this effect was inhibited by the pres-
ence of 1 μM DQBS and completely blocked at a concen-
tration of 10 μM.We next explored the mechanism of the DQBS-
dependent block in Nef-induced downregulation of
MHC-I. An essential first step in this pathway involves
Nef-mediated assembly of a multi-kinase complex in-
cluding an SFK, Syk/Zap-70, and a class I PI3K [20,21].
To determine whether DQBS affected assembly of this
complex, H9 cells were co-infected with recombinant
Hck and Nef vaccinia viruses in the presence or absence
of DQBS. Nef immunoprecipitates were then prepared
and probed for associated Hck and the p85 regulatory
subunit of PI3K. Figure 7B shows that DQBS treatment
reduced the amount of both Hck and p85 associated
with Nef. DQBS treatment also completely blocked Nef-
dependent activation of Zap-70 (Figure 7C). Using an
in vitro kinase assay, we were unable to detect direct in-
hibition of Zap-70 or Hck by DQBS (Figure 7D), sug-
gesting that its effects on kinase activity are mediated
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Figure 6 Inhibition of HIV-1 Nef chimera replication and endogenous SFK activation by DQBS. A) CEM-T4 cells (1 × 104 per well of a 96-
well plate) were infected with wild-type HIV-1 NL4-3, a Nef-defective mutant (ΔNef), or the indicated HIV-1 Nef chimeras in a final culture volume
of 200 μl. Input virus for HIV-1 ΔNef was increased by ten-fold relative to wild-type to compensate for the reduced infectivity and replication of
Nef-defective virus in CEM-T4 cells [41]. DQBS was added to the cultures to final concentrations of 0.3 and 1.0 μM, and viral replication was
determined by p24 ELISA 10 days later. Data are expressed as the mean percent of HIV-1 replication observed in control cultures incubated
with the carrier solvent (0.1% DMSO) ± S.D. from duplicate experiments performed in triplicate. B) CEM-T4 cells were infected with wild-type or
Nef-defective (ΔNef) HIV-1 NL4-3 in the presence of the indicated concentrations of DQBS or the carrier solvent (DMSO). SFK proteins were
immunoprecipitated from infected cell lysates and immunoblotted with an antibody specific for the phosphorylated activation loop tyrosine
(pY418) common to all Src-family members. Controls blots were performed on the cell extracts for HIV-1 Gag proteins (p55, p40, p24), Nef, as
well as actin. Blots from uninfected, untreated cells were also included as a negative control (No virus).
Trible et al. Retrovirology 2013, 10:135 Page 7 of 17
http://www.retrovirology.com/content/10/1/135through Nef. Taken together, these findings suggest that
DQBS prevents Nef-dependent downregulation of MHC-I
by interfering with assembly of the multi-kinase complex
and preventing the activation of Zap-70 downstream.
Inhibition of Zap-70 may also contribute to the anti-
retroviral efficacy of this compound (see Discussion).
Docking studies predict direct binding of DQBS to Nef
The results presented above demonstrate that DQBS in-
hibits Nef-dependent enhancement of HIV-1 replication
across a broad range of Nef subtypes. This compound
also blocks Nef-mediated downregulation of MHC-I by
preventing assembly and activation of downstream kinasesignaling by Nef. These findings suggest that DQBS may
directly target conserved features of the Nef structure. To
explore possible binding sites for DQBS on Nef, we per-
formed docking studies using a crystal structure of Nef
bound to a SFK SH3 domain [35] and AutoDock Vina
[48]. In this structure, the Nef:SH3 complexes pack as di-
mers, with the dimerization interface formed between the
αB helices of the two Nef molecules. Docking analyses
based on the Nef dimer returned two energetically favor-
able binding sites for DQBS, while docking based on a sin-
gle Nef monomer returned three possible binding sites.
Predicted binding site residues within 4 Å of the DQBS
ligand are summarized in Table 1.
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Figure 7 DQBS inhibits Nef-mediated downregulation of MHC-I by preventing assembly of the SFK-ZAP-70-PI3K complex. A) MHC-I
downregulation. H9 cells were infected with a recombinant vaccinia virus carrying Nef-Flag or wild-type vaccinia as a control. Cells were then
treated with DQBS at concentrations of 1 μM or 10 μM for 4 h. The cells were then fixed and processed for flow cytometry using the anti-MHC-I
antibody, W6/32. B) Nef-SFK-PI3K co-precipitation assay. H9 cells were infected with an Hck vaccinia virus either alone or together with the Nef-
Flag virus, followed by treatment with 10 μM DQBS for 4 h prior to harvest. Immunoprecipitates were prepared with the M2 anti-Flag antibody,
and associated Hck and p85 were detected by immunoblotting. Control blots with the cell lysates for p85, Hck and Nef are shown on the right.
C) Zap-70 kinase activation assay. H9 cells were infected with a Zap-70 vaccinia virus either alone or together with the Nef-Flag virus, followed
by treatment with 10 μM DQBS for 4 h prior to harvest. Levels of activated Zap-70 were analyzed by immunoblotting with a phosphospecific
antibody for the activation loop phosphotyrosine residue (pZap-70). Control blots for Zap-70 levels, Nef and actin are also shown. D) DQBS does
not directly inhibit Hck or Zap-70 kinase activity in vitro. Kinase assays were performed with recombinant purified Hck-YEEI and Zap-70 in the
absence or presence of the DQBS concentrations indicated using the Z’Lyte method as described elsewhere [40,45]. As inhibitor controls in the
kinase assay, we observed potent inhibition of Hck by the pan-SFK/Abl inhibitor dasatinib [46] and of Zap-70 by the Syk/Zap-70 inhibitor, BAY
61–3606 [47] (data not shown).
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localizes to the Nef dimer interface, with a predicted bind-
ing energy of −9.0 kcal/mol (modeled in Figure 8A). This
site involves a polar contact with Nef Asn126, a residue
previously implicated in the mechanism of action of an-
other Nef antagonist reported recently, a diphenylpyrazolo
compound known as B9 [45]. In addition, this docking
pose places DQBS in close contact with the side chain of
Asp123, a residue critical for Nef function in MHC-Idownregulation [49]. A recent crystal structure shows that
Nef Asp123 interacts with the μ1 subunit of the clathrin
adaptor protein AP-1, which is linked to later steps in the
MHC-I endocytic pathway [20,50]. The second DQBS
binding site based on the Nef dimer also involves polar
contacts with Asn126 as well as Thr138, and comes in
close proximity to Asp123 (Figure 8B).
Docking routines for DQBS based on an individual
Nef subunit from the same crystal structure returned
Table 1 Docking of the small molecule Nef antagonist DQBS to HIV-1 Nef
Binding site Binding energy (kcal/mol) Nef residues within 4 Å of DQBS
Nef dimer
1 −9.0 Nef subunit 1 (blue in Figure 8): Gln104, Asp108, Pro122, Asp123
Nef subunit 2 (green in Figure 8): Gln104, Asp108, Gln107, Asp111, Leu112, Pro122, Gln125, Asn126, Tyr127
2 −8.3 Pro78, Met79, Thr80, Tyr81, Asp123, Trp124, Asn126, Leu137, Thr138, Phe129, Tyr202
Nef monomer
1 −7.9 Gln104, Gln107, Gln125, Asn126, Tyr127, Thr128, Pro129, Arg134, Leu137, Tyr202
2 −7.9 Met79, Tyr82, Asn126, Leu137, Thr138, Phe139, His193, Tyr202, Phe203
3 −7.7 Leu91, Lys94, Gly95, Gly96, Leu97, Leu100, Arg106, Ile109, Leu110, Trp113
Docking was performed using AutoDock Vina and an X-ray crystal structure of HIV-1 Nef as described under Materials and Methods. For the Nef dimer, two
binding sites were predicted, with a preference for the dimer interface site (Site 1). Analysis using a single Nef monomer from this crystal structure returned three
energetically equivalent sites. The table summarizes the binding energies and predicted binding site residues within 4 Å of the docked ligand. Molecular models
for the two sites predicted from the Nef dimer are shown in Figure 8.
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http://www.retrovirology.com/content/10/1/135two sites with binding energies of −7.9 kcal/mol (Table 1).
Both of these involve Asn126, which was also imp-
licated in docking poses based on the dimer. A third
putative DQBS binding site on Nef (−7.7 kcal/mol) in-
volves Trp113, which is involved in Nef interaction with
the SH3 domains of Src-family kinases (see Figure 3). In
addition, Trp113 is essential for Nef binding to PACS-2, a
trafficking protein critical to the assembly of the multi-
kinase complex that initiates the Nef-dependent MHC-INefA
NefB
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DQBS destabilizes the multi-kinase complex and pre-
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induced MHC-I downregulation (Figure 7). Overall, the
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istic basis for its potent activity against several Nef func-
tions (see Discussion).Site 2
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Figure 9 DQBS induces thermal destabilization of Nef.
A) Differential scanning fluorimetry assays were performed using
recombinant purified Nef and Hck-YEEI proteins in the presence of
DQBS as described under Materials and Methods. Data are plotted
as the change in the mid-point of each thermal melt profile (ΔTm)
as a function of DQBS concentration relative to the DMSO control.
B) ΔTm values were determined for Nef and Hck-YEEI in the presence
of 2,3-diaminoquinoxaline (2,3-DQ) or the kinase inhibitor dasatanib,
each at a concentration of 100 μM. The chemical structures of dasatinib
and the DQBS parent scaffold 2,3-DQ are shown on the right; note that
2,3-DQ is inactive in all Nef and HIV assays tested. In both A and B,
each data point represents an average of 2 to 8 separate DSF experi-
ments, each performed in triplicate.
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scanning fluorimetry
Docking studies presented in the previous section sup-
port direct interaction of DQBS with Nef. To test this
possibility experimentally, we developed a differential
scanning fluorimetry assay [51,52] in which purified re-
combinant Nef is gradually heated in a quantitative PCR
instrument in the presence of the reporter dye, SYPRO
orange. As the temperature rises and Nef unfolds, the
reporter dye gains access to the hydrophobic interior of
the Nef protein, resulting in an increase in dye fluores-
cence. The resulting rise in fluorescence as a function of
temperature eventually reaches a maximum, and the
resulting protein ‘melt curve’ is fit by non-linear regres-
sion analysis to obtain a Tm value (temperature at which
half-maximal thermal denaturation is observed). For
full-length recombinant Nef, we observed a very consist-
ent Tm value of 61.5 ± 0.6°C. This experiment was then
performed over a range of DQBS concentrations. As
shown in Figure 9A, addition of DQBS resulted in a
concentration-dependent decrease in the Tm value, with
a maximum reduction of about 8°C. In contrast to Nef,
DQBS had no effect on the thermal stability of recom-
binant, near-full-length Hck, providing additional evi-
dence that DQBS works by interacting with Nef and not
with its partner kinase. Additional control experiments
show that the unsubstituted 2,3-diaminoquinoxaline
pharmacophore as well as a structurally unrelated com-
pound (the kinase inhibitor dasatinib) had no effect on
the thermal stability of Nef even at concentrations as
high as 100 μM (Figure 9B). Dasatinib, on the other
hand, caused a dramatic increase in the thermal stability
of Hck (Figure 9B), which agrees with the potent inhib-
ition of Hck by this compound (data not shown). These
new data provide important evidence that DQBS inter-
acts directly with the Nef protein, and may destabilize
its quaternary structure and/or interactions with effector
proteins as a possible mechanism of action.
Comparison of the anti-HIV activities of DQBS with other
Nef antagonists
In addition to DQBS, a handful of other compounds
have been reported to bind to Nef and impact its func-
tions (for a review, see Smithgall and Thomas [53]).
These include the diphenylpyrazolodiazene compound
B9 described above, which is predicted to bind to the
Nef dimerization interface [45], as well as DLC27-14,
which was computationally designed to block Nef inter-
action with SH3 domains and may also destabilize the
Nef structure [54,55]. The structures of these com-
pounds are presented in Figure 10A. In a final series of
studies, we compared their activity to that of DQBS in
HIV assays that are influenced by the presence of Nef.
HIV replication assays were performed in U87MG/CD4/CXCR4 cells with all compounds tested at a concentra-
tion of 3 μM. As shown in Figure 10B, both DQBS and
B9 reduced viral replication to levels near or below that
observed with the Nef-defective virus, consistent with
data presented above for DQBS and in previous studies
for B9 [45]. On the other hand, DLC27-14 was less po-
tent, reducing viral replication by about 25% at this con-
centration. Each of these compounds was also tested in
the TZM-bl reporter cell line [56] for effects on early
events in the viral life cycle. Interestingly, only B9 inhib-
ited viral infectivity and gene expression at this concen-
tration, consistent with published results [45]. While
cytotoxicity precluded the evaluation of DQBS at higher
concentrations in this assay, these results suggest that it
may act at later stages of the viral life cycle.
Discussion
In this report we describe the discovery of a unique
antagonist of the HIV-1 accessory protein, Nef, using a
yeast-based screening assay. This assay exploits the
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Figure 10 Comparison of DQBS with other Nef inhibitors on HIV replication and infectivity. A) Structures of the Nef inhibitors B9 and
DLC27-14 (see main text for details). B) HIV-1 replication assays were performed in U87MG/CD4/CXCR4 cells in the absence (DMSO control) or
presence of each compound as described in the legend to Figure 5. Cells infected with an equivalent p24 input of Nef-defective HIV (ΔNef)
are included as a reference control. C) TZM-bl reporter cells, in which the HIV-1 LTR drives transcription of luciferase [56], were infected with
wild-type or Nef-defective (ΔNef) HIV-1 NL4-3 in the absence (DMSO) or presence of each of the Nef inhibitors shown. Viral infectivity was
assessed as luciferase activity 48 h later. This experiment was repeated in triplicate and the data are presented as mean percent infectivity
relative to the DMSO control.
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http://www.retrovirology.com/content/10/1/135growth-suppressive actions of Src-family kinases on
yeast cell growth [26,31]. In our case, we engineered
yeast strains to co-express Nef and the Src-family kinase
Hck, one of the best-characterized Nef target proteins.
Nef interacts with Hck and switches on its kinase activ-
ity by binding to its SH3 domain, resulting in growth ar-
rest. Hit compounds were selected based on their ability
to rescue growth suppression by the Nef:Hck complex.
One advantage of this approach is that non-selective
cytotoxic compounds cannot rescue growth and there-
fore do not score as false positives. Remarkably, two of
the top five compounds identified in the yeast screen
were subsequently found to block Nef-dependent HIV-1
replication in vitro. One of these, the 2,3-diaminoqui-
noxaline analog DQBS, not only blocked Nef-dependent
HIV-1 replication with submicromolar potency across a
wide spectrum of Nef subtypes, but was also shown to
reverse MHC-I downregulation by Nef.
DQBS was isolated from a chemical library biased to-
wards heterocyclic structures that resemble protein kin-
ase inhibitors, raising the possibility that it may target
the ATP-binding site of Nef-activated SFKs or Zap-70rather than Nef directly. However, using an in vitro kinase
assay and recombinant purified Hck and Zap-70, we were
unable to detect direct inhibition of kinase activity by
DQBS. A more likely mechanism of action for DQBS in-
volves direct interaction with Nef, thereby interfering with
recruitment and activation of SFKs and other Nef effector
proteins. This possibility is supported by docking studies,
which predicted several energetically favorable binding
sites for DQBS on the Nef structure. Remarkably, several
of the Nef residues predicted to interact with DQBS have
been previously identified in a similar docking study of the
Nef antagonist, B9, including Gln104, Gln107, and Asn
126 [45]. The observation that two independent screens
yielded Nef antagonists with overlapping predicted bind-
ing sites suggests that this region may represent a hot spot
for Nef inhibitor development. Direct interaction of DQBS
with Nef is supported by differential scanning fluorimetry
assays presented here, which showed that this compound
causes thermal destabilization of the Nef protein in a
concentration-dependent manner.
One exciting feature of DQBS is its potent activity
against Nef-dependent downregulation of MHC-I, which
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surveillance. The extent of MHC-I downregulation in sim-
ian immunodeficiency virus (SIV)-infected macaques cor-
relates directly with the severity of disease progression,
supporting a critical role for this immune evasive mechan-
ism in vivo [57]. A possible mechanism by which DQBS
blocks this critical Nef function is suggested by the way in
which Nef initiates MHC-I downregulation in HIV-
infected cells. During the first two days following infec-
tion, Nef triggers MHC-I downregulation by an endocytic
program termed the signaling mode. By three days post-
infection, Nef switches to a stoichiometric mode of down-
regulation to prevent newly synthesized MHC-I molecules
from reaching the cell surface [20]. One early step in
the signaling mode involves Nef-dependent assembly of
a multi-kinase complex involving a Src-family member
(Hck, c-Src or Lyn, depending upon the cell lineage),
Zap-70 or Syk, and a class I PI3K [20,22]. Data presented
in Figure 7 support a model in which DQBS interferes
with the initial assembly of this kinase complex, resulting
in a complete block in the activation of Zap-70. Control
kinase assays show that DQBS does not impact Zap-70
or Hck activity directly, supporting a mechanism of action
that is mediated through Nef. In addition, computational
docking studies show that DQBS binding may influence
the accessibility of Nef Trp113, which is required
for interaction with SFK SH3 domains as well as the
PACS-2 trafficking protein that triggers SFK/Zap-70/
PI3K complex assembly [22,44].
Interestingly, Zap-70 has also been implicated in HIV-1
replication and viral spread [58,59], suggesting that DQBS
may interfere with HIV-1 replication by blocking Nef-
dependent Zap-70 activation in CEM-T4 cells and other
T-cell hosts. Future work will address whether DQBS can
similarly inhibit HIV-1 replication in macrophages, which
express the Zap-70 homolog, Syk. The finding that Syk
interchanges with Zap-70 in the Nef-assembled multi-
kinase complex in cells of the monocytic lineage supports
this possibility [22]. The potent inhibition of Nef-dependent
HIV-1 replication in U87MG/CD4/CXCR4 cells reported
here may also involve Syk, which exhibits a more wide-
spread expression pattern than Zap70 [60]. Taken to-
gether, these findings support an inhibitory mechanism
in which DQBS binds directly to Nef and interferes with
its activation of a common intermediate (Zap-70 or Syk)
in both the MHC-I downregulation pathway and in
HIV-1 replication.
Another Nef-binding compound, the Streptomyces nat-
ural product derivative known as ′2c’, has also been re-
ported to affect Nef-dependent MHC-I downregulation
[20,61] and viral infectivity. NMR studies showed that 2c
interacts primarily with Nef through a cleft formed by
the central β-sheet and the C-terminal α-helices. While
the 2c binding site is distinct from those for DQBS onNef presented here, neither binding site overlaps with
Nef structural features involved in SH3 binding and SFK
recruitment. These observations suggest an allosteric
mechanism of action for both compounds. Compared to
DQBS, however, the potency of 2c is lower in terms of
both MHC-I downregulation and antiviral activity. This
difference may relate to a weaker binding affinity of 2c
for Nef as well as the possibility that DQBS may occupy
multiple sites on the Nef structure that are important
for MHC-I downregulation as well as viral growth.
Conclusions
Antiretroviral agents currently used for the treatment of
AIDS target the viral reverse transcriptase, integrase and
protease or block virus-host cell fusion [62]. Data pre-
sented here with the compound DQBS support the idea
that the HIV-1 accessory protein Nef represents an alter-
native target for antiretroviral drug action. This com-
pound not only inhibits enhancement of HIV replication
by Nef, but also reverses Nef-mediated downregulation
of MHC-I, raising the exciting possibility that it may
enhance recognition of HIV-infected cells by cytotoxic
T-cells. The growing number of HIV strains resistant to
conventional antiretroviral therapy [63,64] combined
with the lack of an HIV vaccine underscore the need for
new anti-HIV drugs. Work presented here shows that
compounds targeting HIV-1 Nef may provide a new
avenue for anti-HIV therapy, and demonstrates the
potential of a yeast-based, phenotypic screen based on
the complex of an HIV-1 accessory protein with a host
cell kinase as a route to their discovery.
Methods
Yeast expression vectors
Coding sequences for human Csk and Hck as well as HIV-
1 Nef (SF2 strain) were modified by PCR to introduce a
yeast translation initiation sequence (AATA) immediately
5′ to the ATG start codon. The coding sequence for Hck
was subcloned downstream of the Gal10 promoter in the
pYC2/CT vector (Invitrogen), which carries the CEN6/
ARSH4 sequence for low-copy replication. The Csk and
Nef coding sequences were subcloned downstream of the
Gal1 and Gal10 promoters, respectively, in the yeast ex-
pression vector pESC-Trp (Stratagene). The coding se-
quence of the wild-type Hck tail (YQQQP) was modified
by PCR to encode the high-affinity SH2-binding sequence,
YEEIP, as described elsewhere [32,65]. The Nef-PA mu-
tant, in which prolines 72 and 75 are replaced with ala-
nines, has also been described elsewhere [17].
Yeast growth suppression assay
S. cerevisiae strain YPH 499 (Stratagene) was co-
transformed with pESC-Ura (or pYC2/CT) and pESC-
Trp plasmids containing the genes of interest via
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lected for three days at 30°C on standard synthetic drop-
out plates lacking uracil and tryptophan (SD/-U-T) with
glucose as the sole carbon source to repress protein ex-
pression. Positive transformants were grown in liquid
SD/-U-T medium plus glucose, normalized to OD600nm =
0.2 in water, and then spotted in four-fold dilutions onto
SD/-U-T agar plates containing galactose as the sole car-
bon source to induce protein expression. Duplicate plates
containing glucose were also prepared to control for yeast
loading (data not shown). Plates were incubated for three
days at 30°C and imaged on a flatbed scanner. Yeast
patches appear as dark spots against the translucent agar
background. All growth suppression assays were repeated
at least three times starting with randomly selected inde-
pendent transformed clones and produced comparable re-
sults; representative examples are shown. For the liquid
growth assay, yeast strain W303a (gift of Dr. Frank
Boschelli, Wyeth Pharmaceuticals) was co-transformed
with the required plasmids, seeded at an initial density of
OD600nm = 0.05 units in SD/-U-T medium, and incubated
for 21 h at 30°C. The control inhibitor A-419259 was
added with DMSO as carrier solvent to a final concentra-
tion of 0.1%.
Immunoblotting from yeast cultures
Aliquots of the yeast cultures used for the spot assay
were grown in SD/-U-T medium plus galactose for 18 h.
Cells were pelleted, treated with 0.1 N NaOH for 5 min
at room temperature [66], and normalized with SDS-
PAGE sample buffer to 0.02 OD600nm units per μl. Ali-
quots of each lysate (0.2 OD600nm units) were separated
via SDS-PAGE, transferred to PVDF membranes, and
probed for protein phosphotyrosine content with a com-
bination of the anti-phosphotyrosine antibodies PY99
(Santa Cruz Biotechnology) and PY20 (Transduction
Laboratories). Immunoblots were also performed with
antibodies to Csk (C-20; Santa Cruz), Hck (N-30; Santa
Cruz), actin (MAB1501; Chemicon International) and
Nef (monoclonal Hyb 6.2; NIH AIDS Research and
Reference Reagent Program).
Yeast inhibitor screen
Yeast strain W303a was co-transformed with Hck-YEEI
and Nef expression plasmids and grown to an OD600nm of
0.05. Cells (100 μl) were plated in duplicate wells of a 96-
well plate in the presence of each compound from the
ChemDiv kinase-biased inhibitor library (ChemDiv, Inc.,
San Diego, CA). All compounds were initially screened at
10 μM with 0.5% DMSO as carrier solvent. Control wells
contained 0.5% DMSO to define the extent of growth ar-
rest as well as cells transformed with Hck-YEEI plus the
Nef-2PA mutant to define maximum outgrowth. Each
plate also contained wells with 5 μM A-419259 as apositive control for drug-mediated growth reversion. Cul-
tures were incubated at 30°C, and the OD600nm was mea-
sured at 0 and 22 h. Those compounds which induced a
10% or greater increase in yeast growth relative to the
DMSO control were further assayed in triplicate and com-
pared against A-419259-mediated growth reversion. Com-
pounds from this secondary screen which recovered yeast
growth to at least 25% of that observed with A-419259
were obtained in powder form from the provider of the
original library (ChemDiv) and assayed a third time in
triplicate at 1, 3, 10, and 30 μM in comparison with 5 μM
A-419259.HIV assays
HIV-1 replication assays were conducted using the HIV-1
strain NL4-3. Viral stocks were prepared by transfection
of 293 T cells (ATCC) with proviral genomes for the wild-
type, Nef-defective (ΔNef), or Nef chimeras (all based on
NL4-3 backbone) and amplified in the T-cell line, MT2
(NIH AIDS Research and Reference Reagent Program) as
previously described [41,45]. Viral replication was assessed
in the U87MG astroglioma cell line engineered to express
the HIV-1 co-receptors CD4 and CXCR4 or in the
T-lymphoblast cell line, CEM-T4 [41,45]. Both the
U87MG and CEM-T4 cell lines support HIV-1 replication
in a Nef-dependent manner, and were obtained from the
NIH AIDS Research and Reference Reagent Program.
Compounds were solubilized in DMSO, and added to the
cell culture medium 1 h prior to infection with HIV. Viral
replication was monitored for either 4 days (U87MG) or
9 days (CEM-T4) by measuring p24 Gag protein levels in
the culture supernatant using standard ELISA-based tech-
niques. HIV-1 infectivity was measured using the reporter
cell line TZM-bl, in which the HIV LTR drives transcrip-
tion of luciferase [56]. Details of the assay conditions are
described elsewhere [45].Activation of endogenous SFKs by HIV-1 Nef
CEM-T4 cells (1 × 105) were infected with 50 pg p24
equivalents/ml of wild-type HIV-1 NL4-3 or the Nef-
defective mutant in a final culture volume of 10 ml. DQBS
or the DMSO carrier solvent alone were added followed
by incubation for eight days. The infected cells were then
lysed in RIPA buffer and endogenous Src-family kinases
were immunoprecipitated with a pan-specific antibody
and protein-G Sepharose beads as described elsewhere
[41]. Kinase activation was assessed by immunoblotting
each immunoprecipitate with a phosphospecific antibody
against the activation loop phosphotyrosine residue
(pY418) common to all Src family members. Control blots
were performed on cell lysates for HIV-1 Gag proteins
(p55, p40, and p24), Nef, as well as actin as a loading
control.
Trible et al. Retrovirology 2013, 10:135 Page 14 of 17
http://www.retrovirology.com/content/10/1/135MHC-I downregulation assays
H9 T cells were infected with wild-type vaccinia virus or
with a vaccinia recombinant expressing Nef-Flag (moi =
10) for 8 h as described previously [22,42]. Cells were in-
cubated in the presence of DQBS or carrier solvent
alone (DMSO) for 4 h prior to harvest. The cells were
then fixed in 2% paraformaldehyde, washed and resus-
pended in FACS buffer (PBS, pH 7.2, containing 0.5%
FBS) and incubated with mAb W6/32 (anti-MHC-I,
1:4,000) followed by PE-conjugated donkey anti-mouse
IgG (1:1,000; Jackson IR, West Grove, PA). Cells were
analyzed by listmode acquisition on a FACSCalibur (BD)
flow cytometer using CellQuest acquisition/analysis
software (BD) and data analyzed using CellQuest or FCS
express (De Novo Software, Los Angeles, CA).
Co-immunoprecipitation of Nef:kinase complexes
To measure the effect of DQBS on the interaction between
Nef, Hck and class I PI3K, H9 Tcells were co-infected with
wild-type vaccinia virus (moi = 10) or a combination of the
Nef-Flag (moi = 10) and Hck viruses (moi = 12 total). Cells
were treated with 10 μM DQBS at 4 h post-infection and
harvested 4 h later by lysis in PBS containing 1% NP40
supplemented with protease and phosphatase inhibitors.
Nef-Flag was immunoprecipitated with mAb M2-agarose
beads (Sigma) and co-immunoprecipitating Hck (N-30,
Santa Cruz) and p85 (Millipore) were detected by immu-
noblot analysis. Nef-Flag recovery was confirmed by im-
munoblotting with anti-Nef antibodies (AIDS Reagent and
Reference Program). Control blots of cell lysates were per-
formed with actin antibodies (mAb 1501, Millipore). To
measure the effect of DQBS on the Nef-dependent activa-
tion of Zap-70, H9 cells were co-infected with wild-type
vaccinia virus (moi = 6) or the Nef-Flag (moi = 6) and
Zap-70 viruses (moi = 10 total). Infected cells were then
treated with 10 μM DQBS for 4 h prior to harvest and
lysed as described above. The presence of active ZAP-70
was assessed by immunoblotting with a phosphospecific
antibody against the activation loop phosphotyrosine site
(pY319-ZAP-70; clone 2 F3.2, Millipore). Zap-70 (Cell
Signaling) and Nef levels were measured by immuno-
blotting of the clarified cell lysates.
Molecular docking
The structure of DQBS was docked to the crystal struc-
ture of HIV-1 Nef [35] (PDB: 1EFN; without the SH3
domain) using AutoDock Vina [48]. Independent dock-
ing routines were performed using the Nef dimer and a
single Nef monomer. The three-dimensional structures
of the compound and the Nef proteins were first con-
verted from pdb into pdbqt format with MGL Tools
[67]. The Nef structures were kept rigid during the
docking routine, while rotatable bonds in DQBS im-
parted ligand flexibility. A grid box was centered on andcovered each Nef structure. Nef residues predicted to
participate in Nef:DQBS complex formation from the
docking results with the lowest binding energies are pre-
sented in Table 1.
Synthesis of DQBS
The synthesis of all compounds was performed under a
nitrogen atmosphere. Commercially available precursors,
solvents and reagents (Aldrich) were used without add-
itional purification. NMR spectra were recorded on a
Bruker 600 MHz spectrometer; chemical shifts are given
in ppm and are referenced to residual solvent peaks.
4-Chloro-N-(3-chloro-quinoxalin-2-yl)-benzenesulfonamide
(QBS)
4-Chlorobenzenesulfonamide (1.92 g, 10 mmol) was dis-
solved in anhydrous DMF (50 ml). Potassium carbonate
(1.38 g, 10 mmol) was added in one portion, and the reac-
tion mixture was stirred for 10 min. 2,3-Dichloroquinoxa-
line (1.99 g, 10 mmol) was added, and the reaction
mixture was refluxed under N2 for 2.5 h with reaction
progress monitored by TLC (hexanes/ethyl acetate 3:1 as
mobile phase). The reaction mixture was cooled and
added slowly to an aqueous solution of acetic acid (1%,
500 ml) with vigorous stirring. The product precipitated
as grey crystals, which were filtered and dried overnight
in a desiccator (Drierite). Yield 2.32 g, 66%. Rf = 0.7
(hexanes/ethyl acetate 1:1).
4-Chloro-N-[3-(2,3-dihydrobenzo [1,4] dioxin-6-ylamino)-qui-
noxalin-2-yl]-benzenesulfonamide (DQBS)
Compound QBS (354 mg, 1 mmol; above) was dissolved in
xylenes (20 ml). 6-Amino-1,4-benzodioxane (2 mmol,
246 μl) was added and the reaction mixture was refluxed
under N2 for 5 h. The solvent was evaporated under vac-
uum, and DQBS was isolated and purified by column chro-
matography (hexanes/ethyl acetate 9:1 as solvent phase).
The final product formed yellow crystals with a melting
point of 257-258°C. Yield, 61%. Rf = 0.3 (hexanes/ethyl acet-
ate 3:1). 1H NMR (CDCl3, 600 MHz): δ 4.31 (m, 2H), 6.88
(d, J = 9.0 Hz, 1H), 7.15 (dd, J = 9.0 Hz, 2.4 Hz, 1H), 7.29
(dd, J = 1.2 Hz, 1H), 7.36 (td, J = 7.8 Hz, 1.2 Hz, 1H), 7.42
(td, J = 7.8 Hz, 1.2 Hz, 1H), 7.53 (d, J = 9 Hz, 2H), 7.70
(m, 2H), 7.98 (d, J = 8.4 Hz, 2H), 8.19 (br.s, 1H), 11.88 (br.s,
1H). 13C NMR (CDCl3, 150 MHz): δ 64.34, 64.53, 109.36,
113.54, 116.18, 117.28, 124.16, 125.87, 126.60, 126.81, 127.
89, 129.38, 131.99, 134.18, 139.41, 140.14, 140.28, 141.24,
143.43, 144.08. HRMS [C22H18ClN4O4S]
+: calculated, 469.
0732; observed 469.0704.
Differential Scanning Fluorimetry (DSF)
A real-time StepOnePlus qPCR instrument (Applied
Biosystems) and software (version 2.3) were used to per-
form DSF measurements. Recombinant full-length Nef
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purified as described previously [40,41]. DSF assays (20 μl)
were run in triplicate wells in MicroAmp Fast 96-well
qPCR plates sealed with optical adhesive covers (Applied
Biosystems). Baseline DSF profiles were obtained with re-
combinant Nef and Hck-YEEI proteins (1 μM) in bicine
buffer (10 mM bicine, 150 mM NaCl, pH 8.0) and SYPRO
Orange (Sigma) diluted to a 5X working concentration
as described [51,52]. The test compounds DQBS, 2,3-
diaminoquinoxaline (ChemDiv) and dasatinib (LC Labora-
tories) were solubilized in DMSO and diluted into the
DSF assays, followed by incubation for 15 min with each
protein at 4°C prior to the addition of SYPRO Orange.
Parallel reactions were run in the absence of the proteins
to correct for background fluorescence. The final DMSO
concentration in all reactions was 1.1%. For DSF measure-
ments, the qPCR instrument was set to use the ROX
emission filter (≅ 610 nm) without a quencher or passive
reference as recommended by the manufacturer. DSF
mixtures were allowed to equilibrate to 25°C for 2 min,
followed by an increase to 99°C at a 1% temperature ramp
rate (1.6°C/min) with continuous data collection. Data
were corrected for background (no protein controls) and
mean fluorescence intensities were plotted as a function of
temperature. The resulting melt curves were fit to the
Boltzmann sigmoid function using GraphPad Prism 6, and
melt temperature (Tm) values were derived from the mid-
point of the melt transition as described previously
[51,52]. ΔTm values were calculated as the difference be-
tween the Tm values obtained in the presence and absence
of each test compound.Competing interests
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